The lab created active molecular identification tags to be able to track specimens themselves, rather than just their containers.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The firm's 14 percent growth in molecular diagnostics sales was driven primarily by continued strength across its Aptima women's health products globally.
The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.
The company also announced that it has received New York State Department of Health conditional approval for three women's health molecular diagnostic tests.
Revenues from the company's clinical labs segment grew 8 percent this quarter, and revenues from the life sciences business grew 6 percent.
The two companies said they will integrate their technologies to create a sample management and interpretation and reporting system.
The firm sees the new panel as an important step forward in its strategy to further penetrate the molecular diagnostics market with its qPCR products.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Cepheid said this week that it has launched Xpert HPV, a one-hour molecular test for cervical cancer-related human papillomaviruses, in Europe after receiving CE IVD marking.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.